Cardinal Health is trading 7.58% up now at $255.16 after fourth-quarter non-GAAP EPS of $2.91 beat the $2.42 estimate and stronger FY2027 guidance.
- Pharmaceutical and Specialty Solutions profit rose 21% to $645 million on specialty-drug demand, despite revenue missing expectations.
- Management guided FY2027 EPS to $12.40–$12.60 and authorized a $5.0 billion share-repurchase increase.
- Broader indexes are flat; the August 11 earnings release included a one-time $100 million tariff refund, and investors may continue evaluating underlying earnings quality.